146093-46-1

Basic information

• Product Name: 4-(2-Aminoethyl)-1-Boc-piperidine
• Synonyms: 4-(AMINOETHYL)-1-BOC-PIPERIDINE;4-(AMINOETHYL)-1-N-BOC-PIPERIDINE;4-(2-Aminoethyl)-1-N-Boc-piperidine;tert-butyl 4-(2-aminoethyl)piperidine-1-carboxylate;1-N-Boc-4-(Aminoethyl)-piperidine;1-Piperidinecarboxylic acid, 4-(2-aminoethyl)-, 1,1-dimethylethyl ester;4-(Aminoethyl)-1-N-Boc-piperidine Hcl;4-(AMinoethyl)-1-N-Boc-piperidine/tert-butyl 4-(2-aMinoethyl)piperidine-1-carboxylate
• CAS NO: 146093-46-1
• Molecular Formula: C₁₂H₂₄N₂O₂
• Molecular Weight: 228.33
• Product Categories: pharmacetical
• Mol File: 146093-46-1.mol

Chemical Properties

• Boiling Point: 316 °C at 760 mmHg
• Flash Point: 144.9 °C
• Appearance: /
• Density: 1.01 g/cm³
• Vapor Pressure: 0.000422mmHg at 25°C
• Refractive Index: 1.481
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 10.43±0.10(Predicted)
• CAS DataBase Reference: 4-(2-Aminoethyl)-1-Boc-piperidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-Aminoethyl)-1-Boc-piperidine(146093-46-1)
• EPA Substance Registry System: 4-(2-Aminoethyl)-1-Boc-piperidine(146093-46-1)

Safety Data

• Hazard Codes: Xn
• Statements: 36/37/38-22
• Safety Statements: 26-36/37/39
• RIDADR: UN2811
• HazardClass: IRRITANT
• Hazardous Substances Data: 146093-46-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-(2-Aminoethyl)-1-Boc-piperidine is used as a synthetic intermediate for the development of various pharmaceuticals, particularly those targeting the central nervous system. Its presence in the synthesis process aids in the creation of complex molecules that can be used to treat a range of neurological disorders and conditions.
Used in Organic Synthesis:
In the field of organic synthesis, 4-(2-Aminoethyl)-1-Boc-piperidine is used as a versatile building block for the preparation of complex organic molecules. Its structural features allow for the formation of diverse chemical entities, contributing to the advancement of chemical research and the discovery of new compounds with potential applications.
Used in Medicinal Chemistry:
4-(2-Aminoethyl)-1-Boc-piperidine is employed as a key component in medicinal chemistry for the synthesis of biologically active molecules. Its unique structure and functional groups enable the design and creation of new drugs with improved efficacy and selectivity, enhancing the treatment options for various diseases and medical conditions.

InChI:InChI=1/C12H24N2O2/c1-12(2,3)16-11(15)14-8-5-10(4-7-13)6-9-14/h10H,4-9,13H2,1-3H3

Upstream product

• 146093-45-0 t-butyl 4-(2-azidoethyl)piperidine-1-carboxylate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 147699-19-2 tert-butyl 4-{2-[(methylsulfonyl)oxy]ethyl}piperidine-1-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 89151-46-2 tert-butyl 4-(2-iodoethyl)piperidine-1-carboxylate 
• 197569-11-2 4-(cyanomethylidene)piperidine-1-carboxylic acid tert-butyl ester 
• 150022-51-8 tert-butyl 4-(2-(1,3-dioxoisoindolin-2-yl)ethyl)piperidine-1-carboxylate 
• 256411-39-9 tert-butyl 4-(cyanomethyl)piperidine-1-carboxylate 
• 622-26-4 4-(2-Hydroxyethyl)piperidine 
• 135716-09-5 tert-butyl 4-(2-ethoxy-2-oxoethyl)piperidine-1-carboxylate 
• 135716-08-4 tert-butyl 4-(2-ethoxy-2-oxoethylidene)piperidine-1-carboxylate 
• 89151-44-0 4-(2-hydroxyethyl)piperidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 159640-66-1 4-[2-(2-Amino-5-iodo-benzoylamino)-ethyl]-piperidine-1-carboxylic acid tert-butyl ester 
• 151097-96-0 3-[{2-(1-tert-butoxycarbonylpiperidin-4-yl)ethyl}carbamoyl]-5-(4-cyanophenyl)-1,2,4-oxadiazole 
• 163209-81-2 3-[2-(N-Boc-Piperidin-4-yl)ethylaminosulfonyl]benzoic Acid 
• 1101173-90-3 tert-butyl 4-(2-(3,3-diphenylpropylamino)ethyl)piperidine-1-carboxylate 
• 1203719-57-6 4-(2-{3-[3-(4-cyanophenyl)ureidomethyl]benzoylamino}ethyl)piperidine-1-carboxylic acid tert-butyl ester 
• 1613513-24-8 3,5-dichlorobenzyl 4-(2-(3-(3-hydroxyisoxazol-5-yl)propanamido)ethyl)piperidine-1-carboxylate 
• 896103-62-1 tert-butyl 4-(2-(methylamino)ethyl)piperidine-1-carboxylate 

Relevant articles and documents

QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF

Compounds and methods for their preparation and use as therapeutic or prophylactic agents, fo example for treatment of cancer, bacterial or viral diseases by targeting Ectonucleotide Pyrophosphatase/Phosphodiesterase- 1 (ENPP1).

ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF

Disclosed herein are methods and compounds of augmenting and enhancing the production of type I IFNs in vivo. In some embodiments, the compounds disclosed herein are ENPP-1 inhibitors, pharmaceutical compositions, and methods for the treatment of cancer or a viral infection.

Highly potent and selective NaV1.7 inhibitors for use as intravenous agents and chemical probes

The discovery and selection of a highly potent and selective NaV1.7 inhibitor PF-06456384, designed specifically for intravenous infusion, is disclosed. Extensive in vitro pharmacology and ADME profiling followed by in vivo preclinical PK and efficacy model data are discussed. A proposed protein–ligand binding mode for this compound is also provided to rationalise the high levels of potency and selectivity over inhibition of related sodium channels. To further support the proposed binding mode, potent conjugates are described which illustrate the potential for development of chemical probes to enable further target evaluation.

NOVEL BENZODIOXANE-PIPERIDINE DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS FOR TREATING NEUROPSYCHIATRIC DISORDERS

The present invention concerns benzodioxane-piperidine with general formula I: wherein notably: R1 represents one or more identical or different substituent(s) on the benzene ring, each independently representing a hydrogen or halogen atom, or a C1-4 alkyl group, or a C1-4 alkoxy group or a C1-4 hydroxyalkyl group or a C1-4 alkylcarbonyl or an alkoxycarbonyl group or an OH group or an SO2R group with R alkyl, or a CN group, or a CF3 group, or an OCF 3 group; n=1, 2 or 3;m=0 or 1, andR2 represents one or more identical or different substituent(s) on the oxazolidinone or morpholinone ring, each independently representing: a hydrogen atom, a C1-4 alkyl group, or a C1-4 alkoxy group, or a C1-4 hydroxyalkyl group, or an alkylcarbonyl group, or an alkoxycarbonyl group, or an alkoxyphenyl group.

HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS

ABSTRACT The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.

Muscarinic M3 receptor antagonists with (2R)-2-[(1R)-3,3-Difluorocyclopentyl]-2-hydroxyphenylacetamide Structures. Part 2

Optimization of the amine part of our original muscarinic M3 receptor antagonist 1 was performed to identify M3 receptor antagonists that are superior to 1. Compounds carrying a variety of diamine moieties without hydrophobic substituent on the nitrogen atom were screened against the binding affinity for the M3 receptor and the selectivity for M3 over the M1 and M2 receptors. This process led to a 4-aminopiperidinamide (2l) with a Ki value of 5.1 nM and with a selectivity of the M3 receptor that was 46-fold greater than that of the M2 receptor. Further derivatization of 2l by inserting a spacer group or by incorporating alkyl group(s) into the amine part resulted in the identification of an 4-(aminoethyl)piperidinamide 2l-b with a Ki value of 3.7 nM for the M3 receptor and a selectivity for the M3 receptor that was 170-fold greater than that of the M2 receptor.

2,3-diaminopropionic acid derivative

The present invention relates to a 2,3-diaminopropionic acid derivative of the formula (1): STR1 or a pharmaceutically acceptable salt thereof. The compounds of the present invention are useful as a platelet aggregation inhibitor, a cancer metastasis inhibitor, a wound healing agent or a bone resorption inhibitor.

Fibrinogen receptor antagonists

Compounds of the invention have the formula STR1 The compounds have fibrinogen receptor antagonist activity.

Fibrinogen receptor antagonists

Novel fibrinogen receptor antagonists of the formula: X--Y--Z-Aryl-A--B and the pharmaceutically acceptable salts thereof, wherein Aryl is a 5-membered aromatic ring system containing 1 or 2 heteroatoms chosen from N, O or S wherein ring atoms may be unsubstituted or substituted with R5 and wherein S may be substituted with 0, 1 or 2 oxygen atoms; and X comprises various Nitrogen substituents including aromatic or nonaromatic systems; Y comprises, for example, alkyl or alkylaminocarbonylalkyl groups and Z and A are substituents which when present are independently chosen from alkyl or alkyloxyalkyl or other groups as defined herein; B is (a) or (b). The claimed compounds exhibit fibrinogen receptor antagonist activity, inhibit platelet aggregation and are therefore useful in modulating or preventing thrombus formation.